Enjoy complimentary customisation on priority with our Enterprise License!
The Global Immunotherapy Drugs Market size is estimated to grow by USD 111.35 billion, at a CAGR of 11.31% between 2023 and 2028. The increasing prevalence of cancer, driven by factors such as aging populations and lifestyle changes, is leading to a greater demand for cancer treatments and therapies. Growing investments in pharmaceutical technology, such as advancements in drug delivery systems and personalized medicine, are driving innovation in the industry and creating new opportunities for growth. Increasing awareness in patients, fueled by initiatives from healthcare organizations and advocacy groups, is leading to earlier detection and treatment of diseases, further driving market growth.
To learn more about this report, Request Free Sample
The hospitals segment is estimated to witness significant growth during the forecast period. This segment plays an important role in the provision of health care services. Hospitals are the first point of entry for diagnosing, treating, and managing a wide range of diseases. In addition, they provide access to specialists and cutting-edge medical facilities. Furthermore, with the growing acceptance of immunotherapy as an innovative treatment, hospitals have become an essential part of the global market.
Get a glance at the market contribution of various segments Download PDF Sample
The hospitals segment was the largest segment and was valued at USD 56.54 billion in 2018. Moreover, these work by stimulating an individual's immune system to recognize and kill cancer cells, providing a more targeted and potentially more successful treatment. In addition, hospitals are leading the way in adding this to their treatment plans, making sure patients get the best care possible. Furthermore, they support clinical trials, research, and development efforts which is fuelling the growth of this segment which in turn drives the immunotherapy drug market growth.
The presence of the monoclonal antibodies segment has fuelled the growth of the global market. In addition, these antibodies, which are created in laboratories, are designed to bind to and target specific proteins that are present in cancer cells and immune cells. In addition, this selective approach has enabled them to be highly effective in the treatment of a variety of cancers and autoimmune diseases. Furthermore, the monoclonal antibody drug development and approval have seen a dramatic increase in recent years, reflecting the growing prevalence and efficacy of this therapy. Cancer biologics, including advanced immunotherapy drugs, are revolutionizing the treatment landscape by targeting specific cancer cells and enhancing the body’s immune response to fight tumors more effectively. Hence, such factors are fuelling the growth of this segment which in turn will drive the market during the forecast period.
For more insights about the market share of various regions Download PDF Sample now!
North America is estimated to contribute 43% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. Some of the main factors that are fuelling the growth of the market in North America include the increasing prevalence of various types of diseases and allergies such as cancer and tuberculosis in the region. In addition, food allergies contribute to a high share of the investments in the immunotherapy market in the region. For example, according to 2021 data from Food Allergy Research and Education (FARE), 32 million people in the US suffer from food allergies. Each year, 200,000 people in the US require emergency medical care due to food allergies. Furthermore, besides allergies, cancer contributes to a large part of the investment of research. Hence, such factors are driving the market in North America during the forecast period.
Immunotherapy drugs have emerged as a promising avenue for treating a wide array of diseases. Target diseases encompass autoimmune and inflammatory diseases, infectious diseases, and chronic illnesses, driving research collaborations and advancements in biotechnology. Biosimilars offer cost-effective alternatives, particularly in the biopharmaceutical industry, where targeted therapies like interferons and interleukins are gaining traction. With supportive government policies, the focus on immunotherapy extends to segments like autoimmune diseases and vaccines segment, addressing critical areas such as organ failure and cancer, including HER2-positive breast cancer and lung cancer. Immunotherapy drugs are increasingly being researched alongside traditional treatments like doxorubicin to enhance cancer treatment efficacy and overcome the limitations of conventional therapies. Notable drugs like trastuzumab emtansine and Tecentriq represent the cutting edge of targeted therapy, offering hope for patients worldwide.
A key factor shaping the market is the emerging drug development techniques. There are significant advances in immunotherapy drug development which are helping pharmaceutical companies to develop more efficient immunotherapies for the treatment of various diseases. For example, SPIRE immunotherapy is one of the most advanced technologies to treat diseases and is currently being used by various pharmaceutical companies.
Moreover, it uses the MicronJet system and helps in maximizing the immune response of the drug. In addition, the popularity of this technology has been growing due to its ease of use and compatibility. Furthermore, this technology is designed to treat various diseases like allergies, such as cat allergy (Cat-SPIRE), HDM allergy (HDM-SPIRE), grass pollen allergy (Grass-SPIRE), and ragweed pollen allergy (Ragweed-SPIRE). Hence, such factors are driving the market during the forecast period.
The high cost associated with immunotherapy drugs is one of the key challenges hindering the market. One of the major impediments to the availability and affordability of these is their high cost of developing, manufacturing, and marketing. In addition, the main reason is that immunotherapy drugs require extensive clinical research and development, costly manufacturing procedures, and rigorous regulatory approval, all of which contribute to their higher prices.
Moreover, the complexity of immunotherapy medications and their tailored treatment regimen further increase the overall expense. For example, CAR-T cell therapies necessitate the extraction, alteration, and re-fusion of the patient's own immune system, thus adding to the already considerable costs. Hence, such factors are negatively impacting the market which in turn hinders the market growth during the forecast period.
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Market Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
AbbVie Inc: The company offers Actonel, Acular, Alloderm and others.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2024 to 2028, as well as historical data from 2018 to 2022 for the following segments.
You may also interested in below market reports:
The market is witnessing significant growth, driven by its efficacy in treating various conditions, notably cancer and autoimmune diseases. Chronic diseases like cancer account for a substantial portion of healthcare expenditure, prompting research and development in this field. Chemotherapy, while effective, often comes with debilitating side-effects, underscoring the need for alternative treatments like immunotherapy. Vaccines, particularly those targeting cancer segment and autoimmune diseases segment, offer promising avenues for treatment. Key drugs like Opdivo and belimumab are leading the charge in immunotherapy, offering hope to patients with conditions like rheumatoid arthritis and lupus nephritis. Additionally, advancements like mRNA-based vaccine represent the future of medical research, potentially revolutionizing treatment modalities for diseases like HIV.
In addition, regulatory bodies like EMA play a crucial role in approving these drugs for patient use. Patients, especially those suffering from conditions like Lungs cancer, Prostate cancer, and Colorectal cancer, are benefiting from advancements in immunotherapy. Additionally, vaccines targeting cancer have shown promise in reducing Cancer deaths and improving patient outcomes. In the realm of autoimmune diseases, drugs like Dupixent offer relief for conditions such as Prurigo nodularis and Alopecia areata. Moreover, innovative approaches like HIV mRNA-based vaccines, supported by institutions like the National Institute of Health, hold potential in treating diseases like HIV, particularly in the geriatric population.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
163 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 11.31% |
|
Market Growth 2024-2028 |
USD 111.35 billion |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
10.24 |
|
Regional analysis |
North America, Europe, Asia, and the Rest of the World (ROW) |
|
Performing market contribution |
North America at 43% |
|
Key countries |
US, Germany, UK, China, and Japan |
|
Competitive landscape |
Leading companies, Market Positioning of companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
AbbVie Inc., Amgen Inc., AstraZeneca Plc, Bayer AG, BioNTech SE, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Celldex Therapeutics Inc., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Immatics NV, Incyte Corp., Johnson and Johnson, Novartis AG, Pfizer Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., ElevateBio, and Genmab AS |
|
Market dynamics |
Parent market analysis, Market Forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the market forecast period. |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by End-user
7 Market Segmentation by Type
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
